Danske Bank A S grew its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 24.6% in the third quarter, according to its most recent filing with the SEC. The fund owned 85,461 shares of the medical research company’s stock after acquiring an additional 16,900 shares during the period. Danske Bank A S owned about 0.08% of Quest Diagnostics worth $19,918,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. BankPlus Trust Department raised its position in shares of Quest Diagnostics by 3.5% during the third quarter. BankPlus Trust Department now owns 12,661 shares of the medical research company’s stock worth $2,951,000 after purchasing an additional 425 shares during the period. Moors & Cabot Inc. boosted its position in shares of Quest Diagnostics by 10.4% in the 3rd quarter. Moors & Cabot Inc. now owns 2,190 shares of the medical research company’s stock valued at $510,000 after purchasing an additional 206 shares during the period. Allworth Financial LP boosted its position in shares of Quest Diagnostics by 3.9% in the 3rd quarter. Allworth Financial LP now owns 1,741 shares of the medical research company’s stock valued at $369,000 after purchasing an additional 66 shares during the period. R Squared Ltd acquired a new position in shares of Quest Diagnostics in the 3rd quarter valued at $240,000. Finally, CENTRAL TRUST Co increased its stake in Quest Diagnostics by 136.6% in the 3rd quarter. CENTRAL TRUST Co now owns 3,823 shares of the medical research company’s stock worth $891,000 after purchasing an additional 2,207 shares in the last quarter. Institutional investors and hedge funds own 88.06% of the company’s stock.
Quest Diagnostics Price Performance
Shares of NYSE:DGX opened at $261.67 on Tuesday. The company’s fifty day moving average is $241.72 and its two-hundred day moving average is $215.98. The company has a quick ratio of 1.58, a current ratio of 1.70 and a debt-to-equity ratio of 0.70. Quest Diagnostics Incorporated has a 12-month low of $171.18 and a 12-month high of $263.19. The company has a market cap of $28.79 billion, a P/E ratio of 23.52, a price-to-earnings-growth ratio of 2.32 and a beta of 0.55.
Quest Diagnostics Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 27th. Investors of record on Tuesday, January 12th will be given a dividend of $0.86 per share. This represents a $3.44 annualized dividend and a yield of 1.3%. The ex-dividend date of this dividend is Tuesday, January 12th. Quest Diagnostics’s payout ratio is presently 34.26%.
Wall Street Analyst Weigh In
DGX has been the topic of several recent analyst reports. Wall Street Zen upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Tuesday, July 28th. UBS Group reaffirmed a “neutral” rating and set a $250.00 price objective on shares of Quest Diagnostics in a research note on Monday, October 19th. Mizuho raised their target price on shares of Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Robert W. Baird set a $262.00 target price on shares of Quest Diagnostics in a research report on Friday, October 23rd. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $245.00 target price on shares of Quest Diagnostics in a research report on Thursday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, Quest Diagnostics has an average rating of “Moderate Buy” and a consensus price target of $248.70.
Read Our Latest Analysis on Quest Diagnostics
Trending Headlines about Quest Diagnostics
Investors following DGX have been watching these headlines:
- Positive Sentiment: Recent quarterly results provided support: Quest reported EPS of $3.00 and revenue of $3.10 billion, both above estimates, with revenue up 10% year over year.
- Neutral Sentiment: Chief Accounting Officer Michael Deppe sold 11,776 shares for about $3.06 million, reducing his holding by 25.07%. The trade was made under a pre-arranged Rule 10b5-1 plan, which makes it less indicative of a sudden change in outlook. SEC filing
- Negative Sentiment: Zacks Research lowered several future EPS forecasts, including Q1 2027 to $2.61 from $2.72, FY2027 to $11.69 from $11.73, and FY2028 to $12.77 from $12.90. The reductions are small but suggest slightly softer expectations for earnings growth. Q1 EPS estimates cut
Insider Transactions at Quest Diagnostics
In related news, EVP Catherine Doherty sold 22,105 shares of the stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $248.02, for a total value of $5,482,482.10. Following the completion of the sale, the executive vice president directly owned 71,949 shares of the company’s stock, valued at approximately $17,844,790.98. This represents a 23.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. Davis sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $242.72, for a total value of $2,427,200.00. Following the sale, the chief executive officer owned 122,423 shares of the company’s stock, valued at $29,714,510.56. The trade was a 7.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 79,478 shares of company stock worth $19,794,031. 0.88% of the stock is currently owned by company insiders.
Quest Diagnostics Profile
Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.
See Also
- Five stocks we like better than Quest Diagnostics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
